ACADIA Pharmaceuticals (ACAD) Earns Daily Media Sentiment Score of 0.29

News articles about ACADIA Pharmaceuticals (NASDAQ:ACAD) have been trending positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9472463355551 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Several equities analysts have commented on the company. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a report on Friday. Piper Jaffray Companies set a $54.00 price target on ACADIA Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday. ValuEngine raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday. Cowen and Company reissued an “outperform” rating and issued a $46.00 price objective (up from $42.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $43.23.

ACADIA Pharmaceuticals (ACAD) opened at 31.21 on Friday. The company has a 50-day moving average price of $29.35 and a 200 day moving average price of $32.02. ACADIA Pharmaceuticals has a 12 month low of $20.68 and a 12 month high of $40.83. The company’s market capitalization is $3.81 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.17. The business had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The firm’s revenue was up 30400.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) EPS. On average, equities research analysts forecast that ACADIA Pharmaceuticals will post ($2.58) EPS for the current fiscal year.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 38,097 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $30.00, for a total value of $1,142,910.00. Following the transaction, the executive vice president now directly owns 109,253 shares of the company’s stock, valued at approximately $3,277,590. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 54,322 shares of company stock worth $1,699,551. Insiders own 22.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “ACADIA Pharmaceuticals (ACAD) Earns Daily Media Sentiment Score of 0.29” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply